(Q39383647)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23859571%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

Impact of pharmacogenetics on CNS side effects related to efavirenz (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23859571%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23859571%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

Almudena Sánchez Martín

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23859571%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Salvador Cabrera Figueroa

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23859571%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Raquel Cruz Guerrero

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23859571%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Liliana Porras Hurtado

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23859571%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Alfonso Dominguez-Gil Hurlé

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23859571%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

publication date

1 July 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23859571%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23859571%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23859571%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23859571%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

1167-1178

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23859571%20AND%20SRC:MED&resulttype=core&format=json

Causes of the decline in AIDS deaths, United States, 1995-2002: prevention, treatment or both?

5 March 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

The drugs or the disease? Causal attributions of symptoms held by HIV-positive adults on HAART

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Adverse effects of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Clinical implications of CNS penetration of antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous system in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Evaluation of an efavirenz-containing regimen: an open-label, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Higher efavirenz plasma levels correlate with development of insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Hyperhidrosis in association with efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Central nervous system adverse effects with efavirenz: case report and review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

ADME pathway approach for pharmacogenetic studies of anti-HIV therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

CYP2B6 (c.516G→T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

The cellular neurobiology of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Successful efavirenz dose reduction guided by therapeutic drug monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Induction of multiple drug transporters by efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

SNPassoc: an R package to perform whole genome association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.111

21 January 2018

Identifiers

DOI

10.2217/PGS.13.111

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23859571%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference